摘要甲状腺相关性眼病（TAO）对患者的生活质量、心理健康以及社会经济都造成了严重的负面影响，在该病的早期活动期进行治疗的效果较好，目前该病的活动性分期主要采用临床活动性评分（CAS），其存在较多不足之处。近年来， 99Tc m-二亚乙基三胺五乙酸（DTPA）SPECT/CT眼眶显像在TAO的早期诊断、治疗和随访中都显示出重要价值，其可以与CAS互相补充，应用前景广阔。笔者总结了目前该领域的研究进展，提出未来需要更多的研究以期建立标准化的采集和结果分析共识，进一步研究一种新的TAO筛选工具，将 99Tc m-DTPA SPECT/CT眼眶显像与人工智能技术相结合，以便更加精准便捷地指导临床。

abstractsThyroid-associated ophthalmopathy (TAO) leads a significant negative impact on patients' quality of life, mental health and community economy. Treatment in the early active stage of the disease will achieve better efficacy. At present clinical activity score (CAS) is the mainly method of judging disease activity, but it has many shortcomings. Recent studies have suggested that 99Tc m-diethylene triamine pentaacetic acid (DTPA) orbital SPECT/CT shows important value in the early diagnosis, treatment and follow-up of TAO. It can complement with CAS and has a broad application prospect. The authors summarize the current research progress in this field and highlight the need for more research to establish a standardized consensus on collection method and result analysis. Investigating a new tool to judge disease activity which can combine 99Tc m-DTPA orbital SPECT/CT with the artificial intelligence will more accurately and conveniently guide the clinical practice.